BTIG Announces Strategic Leadership Appointments in Healthcare Investment Banking, Hires Karen Flaherty to Bolster MedTech Team

NEW YORK--(BUSINESS WIRE)--BTIG announced today leadership changes within its healthcare investment banking division, appointing a new head of healthcare investment banking along with other changes in senior management across its biotechnology and medical technology verticals. These moves highlight BTIG’s continued growth and expanded presence in the healthcare sector and its dedication to providing best-in-class advisory and capital market services across the healthcare landscape.

Robert Dentice has been named Head of Healthcare Investment Banking and Co-Head of Biotechnology Investment Banking. Mr. Dentice joined the firm in 2024 as Co-Head of Healthcare Investment Banking. He will continue to oversee the firm's strategy, client relationships and deal execution across all healthcare verticals. Mr. Dentice has more than 25 years of investment banking experience. Prior to joining BTIG, he was a Managing Director focused on the Biopharmaceutical sector at Cantor Fitzgerald. Previously, Mr. Dentice held senior positions at HSBC and CIBC World Markets. He has transactional expertise across equity, debt, M&A and restructuring.

K.C. Stone has been named Co-Head of Biotechnology Investment Banking. Mr. Stone’s career spans more than 25 years in the industry. He has been with BTIG since 2012 and has a long history of working with emerging growth companies from seed-stage to publicly traded institutions, and with the investors who fund them. Prior to joining BTIG, Mr. Stone worked at Wedbush where he ran the Life Science Investment Banking group. Prior to that, he ran the Private Placement groups at Wedbush PacGrow and Pacific Growth Equities.

Together, they will lead the continued expansion of BTIG’s biotech franchise focusing on emerging and innovative companies across the sector.

In addition, the firm has named Karen Flaherty and Mark Secrest Co-Heads of MedTech Investment Banking. Ms. Flaherty joins the firm as a Managing Director with strong expertise in executing M&A and private and public financing transactions on behalf of medical device companies throughout her 25-year career. Previously, she served as the Global Head of Medical Device Investment Banking at Wells Fargo and Deutsche Bank. Earlier in her career, she was an Executive Director, Healthcare Investment Banking at J.P. Morgan Securities.

Mr. Secrest has been with the firm since 2016. He has extensive M&A and transactional expertise, with a deep understanding of the medical devices, life sciences tools and diagnostics landscape. Mr. Secrest has over 25 years of investment banking experience. Previously, he was a Managing Director and Head of Medical Devices M&A within the Healthcare Investment Banking Group at Stifel. Prior to that, he was Head of Medical Devices M&A and Chairman of the Fairness Opinion Review Committee at Cowen. Earlier in his career, Mr. Secrest spent time in the M&A Groups at UBS Securities and Kidder, Peabody.

Together, Ms. Flaherty and Mr. Secrest will lead the MedTech practice advising clients across devices, diagnostics, digital health and tools. Their combined experience and client focus position the group to capitalize on significant growth opportunities within the sector.

“This reorganization reflects our commitment to aligning top talent with our clients’ evolving needs across the healthcare ecosystem,” said Anton LeRoy, CEO of BTIG. “With a deep bench of experienced professionals and a sharpened sector focus, we are well positioned to deliver exceptional service and solutions for our clients.”

About BTIG

BTIG is a global financial services firm specializing in institutional trading, investment banking, research and related brokerage services. With an extensive global footprint and more than 700 employees, BTIG, LLC and its affiliates operate out of 20 cities throughout the U.S., and in Europe, Asia and Australia. BTIG offers execution, expertise and insights for equities, equity derivatives, ETFs and fixed income, currency and commodities. The firm’s core capabilities include global execution, portfolio, electronic and outsource trading, investment banking, prime brokerage, capital introduction, corporate access, research and strategy, commission management and more.

About BTIG Investment Banking and Capital Markets

BTIG’s Investment Banking and Capital Markets groups engage with clients and institutional investors on mergers and acquisitions, public offerings including IPOs and follow-on offerings, ATMs, SPACs, private placements and PIPEs, convertibles, debt and loans, buybacks, liquidity solutions, and venture capital, private equity transactions.

Disclaimer: https://www.btig.com/disclaimer.aspx